Toxic epidermal necrosishttps://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis
Ko te Toxic epidermal necrosis he momo tauhohenga kiri kino. Ko ngā tohu tuatahi ko te kirikiti me ngā tohu rewharewha. Ka torutoru ngā rā i muri mai, ka timata te kiri ki te opu, te tihoranga, ā, ka puta he wāhi kirikiri māmae. He mea nui kia uru mai ngā kiriuhi mucous, pērā i te waha. Ko ngā raruraru ko te mate wai, te sepsis, te pneumonia, me te ngoikore o te ōkāna maha.

Ko te tino take ko ētahi rongoā pērā i te lamotrigine, carbamazepine, allopurinol, sulfonamide antibiotic, me te nevirapine. Ko ngā mea mōrearea ko te HIV me te systemic lupus erythematosus. I te nuinga o te wā ka mahia ngā maimoatanga i te hohipera, pērā i te wāhi wera, i te wāhanga tiaki kaha rānei.

○ Maimoatanga
He mate kino tēnei; ki te pāngia tō ngutu, waha rānei, ka pupuhi tō kiri, haere wawe ki tō taikaha.
Me whakamutua ngā rongoā whakapae (hei tauira, ngā patupaturopi, ngā rākau taero anti‑inflammatory kore‑steroidal).

☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
  • Te mate kiri āhua o Toxic epidermal necrosis
  • TENS – rā 10
  • Necrolysis epidermalis toxica
  • Ka tere haere te opūpū o te atamira, ka uru ki te tinana katoa i roto i ngā rā torutoru.
References Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management 34577817 
NIH
Ko te Stevens-Johnson Syndrome (SJS) me te Toxic Epidermal Necrolysis (TEN) he āhuatanga e pā ana ki te kiri, ā, ka pā ki te necrosis me te whakaheke. Mō te maimoatanga, he tino whai hua te cyclosporine mō te SJS, ā, ko te huinga o te immunoglobulin (IVIg) me ngā corticosteroids he pai ake mō ngā keehi o te SJS me te TEN.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
 Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 36469487
Ko te Toxic epidermal necrolysis (TEN) he tauhohenga kiri kino nā ētahi rongoā me ngā mahi a te pūnaha aukati, ka puta te wehenga nui o te paparanga kiri o waho (epidermis), ka pā ki te 30 % o te mata o te tinana. Neke atu i te 20 % te nui o te mate mō te TEN, i te nuinga o ngā wā ka pā te mate me te uaua o te manawa. Ko te whakamutu i te rongoā, te whakarato i te manaaki tautoko, me te whakamahi i ētahi atu maimoatanga hei whakapai ake i te putanga. Ko ngā rangahau o tata nei i whakaatu ko ngā rāau taero pērā i te cyclosporine, te aukati alpha necrosis factor, me te whakakotahitanga o te globulin aukati me ngā corticosteroids ka taea te awhina, i runga i ngā whakamātautau me ngā tātaritanga o ngā rangahau maha.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
 Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review 32520664 
NIH
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.